(October 2007)

The Society for Endocrinology has released a position statment on the use of dopamine agonists in endocrine disorders.

Dopamine agonists are routinely used in the treatment of pituitary disorders such as Hyperprolactinaemia and Acromegaly. This statement follows reports earlier this year that the use of the dopamine agonists pergolide and cabergoline in the management of Parkinson’s disease is associated with cardiac valve fibrosis.

To read the position statement:  SfE Position Statement

About the Society for Endocrinology

The Society for Endocrinology (SfE) is the major British society representing scientists, clinicians and nurses who work with hormones. They aim to advance education and research in endocrinology for the public benefit and to promote endocrinology and hormone awareness to the wider community.  The Society for Endocrinology played an integral part in the creation of The Pituitary Foundation in 1994 and the SfE continues to provide assistance, guidance and support to The Foundation.

To learn more:  www.endocrinology.org

Please contact The Foundation if you have any queries:  helpline@pituitary.org.uk or 0845 450 0375